Marco leads Blue Earth Diagnostics, an established global molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer.  Blue Earth Diagnostics’ clinical focus is exclusively on cancer, with an expanding pipeline in disease states. Blue Earth Diagnostics’ strategy is to apply its knowledge and expertise to developing promising cancer radiopharmaceuticals for imaging.

Marco Campione brings more than 25 years of industry experience to his role as President & Chief Executive Officer.

He lived and worked in multiple countries around the world.  Prior to joining Blue Earth Diagnostics from GE HealthCare, he served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc.

He was responsible for the Pharmaceutical Diagnostics business unit in North America, with oversight for its strategy, management, and overall commercial operations throughout the United States and Canada.

Amongst other top management roles at GE HealthCare, Marco served as President and CEO of Southern Europe.

He also served as President of the Italian Medical Device Industry Association with Confindustria.  Before joining GE HealthCare, Marco worked at FiatAvio as integrated logistic support leader for military engines and beforehand served the Italian Military an Anti-aircraft Artillery Technical Control Officer.

He is a Board Member of the Massachusetts Prostate Cancer Coalition, and a Committee Member of the Richi Childhood Cancer Foundation.

Born in Milan, Italy, Marco holds both Italian and Swiss citizenships.  He is an Engineering graduate of the Polytechnic of Turin (BE, ME), and received his MBA from University of Turin, and La Sorbonne, Paris.  Marco lives in the Greater Boston area with his wife Rossella and their son Francesco. Off the clock, he enjoys reading, travelling, and playing tennis.

Dr. Teoh, Blue Earth Diagnostics’ Chief Medical Officer (CMO), reports to CEO Marco Campione. Eugene joined the Company in 2018 as European (EU) Medical Director and was subsequently promoted to Vice President (VP) Clinical Development. Prior to joining Blue Earth Diagnostics, Eugene served as a consultant and investigator to the Company in research to advance its prostate cancer pipeline. Eugene obtained his medical degree from Imperial College School of Medicine, in London, UK, and completed his initial medical training in Oxford and London. This was followed by specialist training in radiology at Oxford, leading to board-certification in radiology with sub-specialization in diagnostic nuclear medicine. Eugene is a member of the Royal College of Physicians and a Fellow of the Royal College of Radiologists in the UK, and holds a doctorate in cancer imaging from the University of Oxford. He has published his research in prestigious medical journals and presented at a variety of national and international meetings.

Fabrizio Fusi is the Chief Financial Officer at Blue Earth Diagnostics. He joined Blue Earth Diagnostics in 2024. Fabrizio has more than 25 years of experience in finance and management consultancy. Prior to joining Blue Earth Diagnostics, he held finance leadership positions with GSK such as finance lead for the Oncology franchise and for the Oncology US organization. He also held senior positions with various management consultancies including the Boston Consulting Group. Fabrizio has a Master of Science in Economics from Università Bocconi (Milan, Italy).

Jonathan Fitzpatrick is the Vice President Human Resources at Blue Earth Diagnostics. He joined Blue Earth Diagnostics in 2020. Jonathan has more than 24 years of experience in Human Resources, the majority of which has been spent with the Bracco Group which he joined in 2002. In those 24 years of careers he held various HR roles, leading HR for the Canadian operations of Bracco. He holds a Bachelor of Science in Industrial Relations from the University of Montreal and is a Chartered Human Resources Professional.

Caroline Foxton brings more than 20 years’ experience in oncology drug discovery and drug development to her role as Vice President, Innovation and Strategy at Blue Earth Diagnostics. She joined the company in 2021. Prior to Blue Earth, Caroline worked for Cancer Research UK within the Commercial Partnerships team and the Centre for Drug Development, providing strategic leadership to support the evaluation and development of novel technologies, often in partnership with industry. For nearly a decade, she worked for Cancer Research Technology Ltd as a Cell Biology Group Leader, delivering drug discovery programmes.  Caroline’s academic training includes a BSc (Hons) in Biochemistry and a PhD in Cell Biology, both from the University of Southampton UK, after which she undertook 5 years of post-doctoral research in the field of translational oncology, funded by Imperial Cancer Research Fund in association with Centocor Inc. 

Matthew Miller brings more than 20 years’ experience in nuclear medicine and clinical trial research to his role as Head of Research & Development at Blue Earth Diagnostics. Matthew joined the company at its outset in 2014, initially as Head of Imaging and subsequently as Vice President of R&D Operations. Prior to Blue Earth, Matthew was a Project Leader within the Imaging R&D division at GE Healthcare, overseeing PET oncology clinical trials in Europe, USA, and Asia. He has previously held positions as a Principal Medical Physicist within Imaging R&D, GE Healthcare, and as a Nuclear Medicine Physicist at the Royal London Hospital, London. Matthew has a BSc in Theoretical Physics from the University of Nottingham, a MSc in Medical Physics from the University of Surrey and a PhD in Medical Physics from the Medical Research Council Cyclotron Unit, Hammersmith Hospital, London, in association with the University of Surrey.

Terri Wilson is the President of Blue Earth Diagnostics Inc., and a member of its Board of Directors. She joined Blue Earth Diagnostics in 2016. Terri is passionate about how policy can impact access to both diagnostic imaging and therapy for patients fighting cancer.  Terri has more than 20 years of experience in the nuclear medicine industry. Prior to joining Blue Earth Diagnostics, she held leadership positions of increasing responsibility in sales, marketing, and market access at organizations such as PETNET Solutions, Siemens, Cardinal Health, and MITA (Medical Imaging & Technology Alliance). She began her career as a nuclear medicine technologist. Terri holds a B.S. in Nuclear Medicine from the University of Missouri and an MBA with a focus on Pharmaceutical Marketing from Saint Joseph’s University in Philadelphia, PA.

Michael Wysocki is the Senior Vice President, Global Sales, of Blue Earth Diagnostics Inc. In this role, Mike leads sales in the U.S. and international markets. He brings two decades of commercial leadership experience in the healthcare sector with significant imaging industry expertise. Prior to joining Blue Earth Diagnostics from Rapid Micro Biosystems, he served as the Senior VP of Global Sales & Marketing at this innovative life sciences company providing mission critical automation solutions to help companies drive efficient manufacturing and fast, safe release of healthcare products. Prior to Rapid, he spent approximately 19 years at GE and GE Healthcare growing various business segments ranging from PET/CT scanners to SPECT cameras to diagnostic radiopharmaceuticals. His passion for working closely with customers to solve their most difficult challenges, building strong diverse teams, and designing winning strategies for growth have been consistent throughout his professional journey. He is a graduate of Boston College, and he holds a Bachelor of Science in Biology (Pre-Medical).